Allergy Therapeutics has announced positive results from its pivotal Phase III trial of Grass MATA MPL, a short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate for the treatment of allergic rhinoconjunctivitis due to grass pollen. The trial met its primary endpoint, demonstrating a highly statistically significant reduction in Combined Symptom & Medication Score (CSMS) compared to placebo over the peak pollen season. Secondary endpoints, including CSMS during the entire grass pollen season, daily medication and symptom scores, and quality-of-life scores, also showed statistical significance. The trial also showed a strong induction of the protective biomarker IgG4 and an acceptable safety profile. The company plans to hold scientific advice meetings with health authorities in Q1 2024 to discuss plans for a marketing authorisation application.